Skip to main content
. Author manuscript; available in PMC: 2010 May 18.
Published in final edited form as: Vaccine. 2009 Apr 3;27(23):3045–3052. doi: 10.1016/j.vaccine.2009.03.026

Table 3.

Cytokine/Chemokine Production After RSV Challenge of Mice Treated with TLR Agonists during FI-RSV immunization or during RSV challenge

Day After Challenge Treat at Priming Treat at Challenge IL-13c Eotaxin IFN-γ MIP-1α MIP-1β
Day 4 PBS PBS 420 ± 97 1515 ± 533 683 ± 143 200 ± 62 341 ± 67
CpG PBS 23 ± 7a 93 ± 35a 1451 ± 280 164 ± 39 301 ± 64
TLR7/8 agonist PBS 531 ± 39 1699 ± 275 1155 ± 144 306 ± 29 488 ± 67
CpG + TLR7/8 PBS 110 ± 24a 397 ± 85 a 1813 ± 265 167 ± 25 450 ± 88
PBS CpG 1812 ± 42a 816 ± 73 731 ± 145 362 ± 36a 484 ± 30
PBS TLR7/8 agonist 288 ± 54 848 ± 96 1147 ± 412 320 ± 53 403 ± 41
PBS CpG + TLR7/8 188 ± 48a 910 ± 141 652 ± 106 707 ± 108a 644 ± 105
Day 7 PBS PBS 112 ± 15 1587.6 ± 240.4 58 ± 8 108 ± 9 199 ± 38
CpG PBS ND a,b 269 ± 18a 83 ± 15 110 ± 10 111 ± 12
TLR7/8 agonist PBS 220 ± 42 2469 ± 432 122 ± 20a 167 ± 25 159 ± 25
CpG + TLR7/8 PBS 69 ± 39 234 ± 42a 47 ± 4 66 ± 6 a 81 ± 31
PBS CpG 107 ± 7 2391 ± 271 226 ± 31a 810 ± 27 a 493 ± 30 a
PBS TLR7/8 agonist 63 ± 15 1588 ± 377 137 ± 22a 192 ± 27 158 ± 58
PBS CpG + TLR7/8 103 ± 36 1708 ± 209 237 ± 21a 520 ± 45 a 262 ± 50
a

Statistically significant relative mice treated with PBS at both priming and challenge, p<0.05.

b

ND = not detected

c

Changes in IL-4, IL-5, and IL-13 levels paralleled each other. For clarity and conciseness, only IL-13 data are shown as representative of type 2 cytokine production.